Shareholder Meeting - FSD Pharma Inc. held its annual general and special meeting of shareholders on June 29, 2023, with 148 shareholders represented, holding 66.67% of Class A Shares and 20.94% of Class B Shares[2] - The election of directors resulted in high approval rates, with Anthony Durkacz receiving 99.94% of votes for his position[3] - Shareholders re-appointed MNP LLP as the auditor and approved the Equity Incentive Plan and Stock Option Plan[5] - The company plans to change its name and stock symbol, pending board approval, without further shareholder consent[5] Drug Development - FSD Pharma has three drug candidates in development, focusing on inflammatory diseases and mental health disorders[9] - The lead compound, FSD201, is a proprietary ultra-micronized PEA formulation aimed at treating inflammatory diseases[9] - Lucid Psychss Inc. is developing compounds for mental health disorders and addressing acute medical needs related to drug abuse[9] - The company acknowledges inherent risks in drug development, including the uncertainty of clinical trial outcomes and regulatory approvals[11] Forward-Looking Statements - FSD Pharma's forward-looking statements are based on assumptions that may not prove correct, highlighting the potential for actual results to differ materially[10] - The company does not undertake any obligation to publicly update or revise forward-looking statements except as required by law[12]
FSD Pharma(HUGE) - 2023 Q2 - Quarterly Report